Display options
Cite
Choi YH, Cotterchio M, McKeown-Eyssen G, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. 2009;7(1):14doi: 10.1186/1897-4287-7-14.
Choi, Y. H., Cotterchio, M., McKeown-Eyssen, G., Neerav, M., Bapat, B., Boyd, K., Gallinger, S., McLaughlin, J., Aronson, M., & Briollais, L. (2009). Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hereditary cancer in clinical practice, 7(1), 14. https://doi.org/10.1186/1897-4287-7-14
Choi, Yun-Hee, et al. "Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario." Hereditary cancer in clinical practice vol. 7,1 (2009): 14. doi: https://doi.org/10.1186/1897-4287-7-14
Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, Gallinger S, McLaughlin J, Aronson M, Briollais L. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. 2009 Aug 23;7(1):14. doi: 10.1186/1897-4287-7-14. PMID: 19698169; PMCID: PMC2744657.
Copy Download .nbib Format: NLM
Share it on

Hered Cancer Clin Pract. 2009 Aug 23;7(1):14. doi: 10.1186/1897-4287-7-14.

Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario.

Hereditary cancer in clinical practice

Yun-Hee Choi, Michelle Cotterchio, Gail McKeown-Eyssen, Monga Neerav, Bharati Bapat, Kevin Boyd, Steven Gallinger, John McLaughlin, Melyssa Aronson, Laurent Briollais

Affiliations

  1. Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Toronto, Canada. [email protected]

PMID: 19698169 PMCID: PMC2744657 DOI: 10.1186/1897-4287-7-14

Abstract

BACKGROUND: Several DNA mismatch repair (MMR) genes, responsible for the majority of Lynch Syndrome cancers, have been identified, predominantly MLH1 and MSH2, but the risk associated with these mutations is still not well established. The aim of this study is to provide population-based estimates of the risks of colorectal cancer (CRC) by gender and mutation type from the Ontario population.

METHODS: We analyzed 32 families segregating MMR mutations selected from the Ontario Familial Colorectal Cancer Registry and including 199 first-degree and 421 second-degree relatives. The cumulative risks were estimated using a modified segregation-based approach, which allows correction for the ascertainment of the Lynch Syndrome families and permits account to be taken for missing genotype information.

RESULTS: The risks of developing CRC by age 70 were 60% and 47% among men and women carriers of any MMR mutation, respectively. Among MLH1 mutation carriers, males had significantly higher risks than females at all ages (67% vs. 35% by age 70, p-value = 0.02), while the risks were similar in MSH2 carriers (about 54%). The relative risk associated with MLH1 was almost constant with age (hazard ratio (HR) varied between 5.5-5.1 over age 30-70), while the HR for MSH2 decreased with age (from 13.1 at age 30 to 5.4 at age 70).

CONCLUSION: This study provides a unique population-based study of CRC risks among MSH2/MLH1 mutation carriers in a Canadian population and can help to better define and understand the patterns of risks among members of Lynch Syndrome families.

References

  1. Genet Epidemiol. 2005 Jul;29(1):36-50 - PubMed
  2. J Med Genet. 2003 Mar;40(3):208-13 - PubMed
  3. Nucleic Acids Res. 2002 Jun 15;30(12):e57 - PubMed
  4. Hum Mol Genet. 1997 Jan;6(1):105-10 - PubMed
  5. Nucleic Acids Res. 2002 Sep 1;30(17):3894-900 - PubMed
  6. J Gastrointest Surg. 1998 Jan-Feb;2(1):67-71 - PubMed
  7. Int J Cancer. 1999 Apr 12;81(2):214-8 - PubMed
  8. Genome Res. 2001 May;11(5):863-74 - PubMed
  9. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6853-61 - PubMed
  10. Gastroenterology. 1999 Jun;116(6):1453-6 - PubMed
  11. J Clin Oncol. 2001 Oct 15;19(20):4074-80 - PubMed
  12. Eur J Cancer Prev. 1994 Jul;3(4):321-7 - PubMed
  13. Chronic Dis Can. 2000;21(2):81-6 - PubMed
  14. Cancer Res. 1998 Nov 15;58(22):5248-57 - PubMed
  15. Hum Genet. 1999 Feb;104(2):167-76 - PubMed
  16. Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10 - PubMed
  17. Am J Hum Genet. 2000 Mar;66(3):1119-31 - PubMed
  18. Dis Colon Rectum. 2002 Sep;45(9):1223-32 - PubMed
  19. Gastroenterology. 2005 Aug;129(2):415-21 - PubMed
  20. Genet Epidemiol. 2004 Sep;27(2):109-17 - PubMed
  21. J Med Genet. 2005 Jun;42(6):491-6 - PubMed
  22. Hum Hered. 2008;66(4):238-51 - PubMed
  23. Gastroenterology. 1996 Apr;110(4):1020-7 - PubMed
  24. Br J Cancer. 2000 Dec;83(12):1643-5 - PubMed
  25. J Natl Cancer Inst. 2002 Aug 21;94(16):1221-6 - PubMed
  26. J Med Genet. 1999 Feb;36(2):97-102 - PubMed
  27. Int J Cancer. 1995 Dec 20;64(6):430-3 - PubMed
  28. Cancer. 1999 Dec 1;86(11 Suppl):2457-63 - PubMed
  29. Clin Gastroenterol Hepatol. 2006 Apr;4(4):489-98 - PubMed

Publication Types

Grant support